nach oben

Strahlentherapie und Onkologie

Erschienen in:

19.04.2017 | Original Article

Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer

verfasst von: Ichiro Ogino, M.D., Shigenobu Watanabe, Kentaro Sakamaki, Yuka Ogino, Chikara Kunisaki, Kazuo Kimura

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the dose–volume parameters of the pericardium and heart in order to reduce the risk of radiation-induced pericardial effusion (PE) and symptomatic PE (SPE) in esophageal cancer patients treated with concurrent chemoradiotherapy.

Methods

In 86 of 303 esophageal cancer patients, follow-up CT was obtained at least 24 months after concurrent chemoradiotherapy. Correlations between clinical factors, including risk factors for cardiac disease, dosimetric factors, and the incidence of PE and SPE after radiotherapy were analyzed using Cox proportional hazard regression analysis. Significant dosimetric factors with the highest hazard ratios were investigated using zones separated according to their distance from esophagus.

Results

PE developed in 49 patients. Univariate analysis showed the mean heart dose, heart V₅–V₅₅, mean pericardium dose, and pericardium V₅–V₅₀ to all significantly affect the incidence of PE. Additionally, body surface area was correlated with the incidence of PE in multivariate analysis. Grade 3 and 4 SPE developed in 5 patients. The pericardium V₅₀ and pericardium D₁₀ significantly affected the incidence of SPE. The pericardium V₅₀ in patients with SPE ranged from 17.1 to 21.7%. Factors affecting the incidence of SPE were the V₅₀ of the pericardium zones within 3 cm and 4 cm of the esophagus.

Conclusion

A wide range of radiation doses to the heart and pericardium were related to the incidence of PE. A pericardium V₅₀ ≤ 17% is important to avoid symptomatic PE in esophageal cancer patients treated with concurrent chemoradiotherapy.

Adams MJ, Lipshultz SE, Schwartz C, Fajardo LF, Coen V, Constine LS (2003) Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol 13(3):346–356. doi:10.1016/S1053-4296(03)00026-2 CrossRefPubMed

Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99(5):365–375. doi:10.1093/jnci/djk064 CrossRefPubMed

Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ, Panel ACSE (2007) American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25(25):3991–4008. doi:10.1200/JCO.2007.10.9777 CrossRefPubMed

Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W, Pascutto C, Franchini P, Lazzarino M (2006) Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin’s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 12(21):6487–6493. doi:10.1158/1078-0432.CCR-06-1420 CrossRefPubMed

Hancock SL, Donaldson SS, Hoppe RT (1993) Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 11(7):1208–1215CrossRefPubMed

Hull MC, Morris CG, Pepine CJ, Mendenhall NP (2003) Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 290(21):2831–2837. doi:10.1001/jama.290.21.2831 CrossRefPubMed

Kaplan BM, Miller AJ, Bharati S, Lev M, Grais MI (1997) Complete AV block following mediastinal radiation therapy: electrocardiographic and pathologic correlation and review of the world literature. J Interv Card Electrophysiol 1(3):175–188CrossRefPubMed

Beukema JC, van Luijk P, Widder J, Langendijk JA, Muijs CT (2015) Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol 114(1):85–90. doi:10.1016/j.radonc.2014.11.037 CrossRefPubMed

Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ (2011) Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 79(1):10–18. doi:10.1016/j.ijrobp.2009.10.058 CrossRefPubMed

10.

Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, Komaki R, Liao Z (2008) Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 70(3):707–714. doi:10.1016/j.ijrobp.2007.10.056 CrossRefPubMed

11.

Ogino I, Watanabe S, Iwahashi N, Kosuge M, Sakamaki K, Kunisaki C, Kimura K (2016) Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer. Strahlenther Onkol 192(6):359–367. doi:10.1007/s00066-016-0956-1 CrossRefPubMed

12.

Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837–1847CrossRefPubMed

13.

Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H, Hanada T, Shiraishi Y, Kitagawa Y, Fukuda K (2013) Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys 87(3):487–493. doi:10.1016/j.ijrobp.2013.07.008 CrossRefPubMed

14.

Tamari K, Isohashi F, Akino Y, Suzuki O, Seo Y, Yoshioka Y, Hayashi Y, Nishida T, Takehara T, Mori M, Doki Y, Ogawa K (2014) Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy. Anticancer Res 34(12):7389–7393PubMed

15.

Kardon DE, Borczuk AC, Factor SM (2000) Mechanism of pericardial expansion with cardiac enlargement. Cardiovasc Pathol 9(1):9–15CrossRefPubMed

16.

Kawaguchi G, Sasamoto R, Abe E, Ohta A, Sato H, Tanaka K, Maruyama K, Kaizu M, Ayukawa F, Yamana N, Liu J, Takeuchi M, Kobayashi M, Aoyama H (2015) The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. Radiat Oncol 10:31. doi:10.1186/s13014-015-0337-4 CrossRefPubMedPubMedCentral

17.

Kumekawa Y, Kaneko K, Ito H, Kurahashi T, Konishi K, Katagiri A, Yamamoto T, Kuwahara M, Kubota Y, Muramoto T, Mizutani Y, Imawari M (2006) Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol 41(5):425–432. doi:10.1007/s00535-006-1771-8 CrossRefPubMed

18.

Taylor CW, McGale P, Darby SC (2006) Cardiac risks of breast-cancer radiotherapy: a contemporary view. Clin Oncol (R Coll Radiol) 18(3):236–246CrossRef

19.

Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D, Prosnitz LR, Marks LB (2001) Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 49(4):1023–1028CrossRefPubMed

20.

Chello M, Mastroroberto P, Romano R, Zofrea S, Bevacqua I, Marchese AR (1996) Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis. Cardiovasc Surg 4(2):222–226CrossRefPubMed

21.

Konski A, Li T, Christensen M, Cheng JD, Yu JQ, Crawford K, Haluszka O, Tokar J, Scott W, Meropol NJ, Cohen SJ, Maurer A, Freedman GM (2012) Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol 104(1):72–77. doi:10.1016/j.radonc.2012.04.016 CrossRefPubMedPubMedCentral

22.

Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M, Ito H, Yamashita T (2009) Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 75(1):122–128. doi:10.1016/j.ijrobp.2008.10.075 CrossRefPubMed

23.

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174CrossRefPubMed

24.

Munch S, Aichmeier S, Hapfelmeier A, Duma MN, Oechsner M, Feith M, Combs SE, Habermehl D (2016) Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT. Strahlenther Onkol 192(10):722–729. doi:10.1007/s00066-016-1020-x CrossRefPubMed

25.

Fleckenstein J, Kremp K, Kremp S, Palm J, Rube C (2016) IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: a direct comparison of PET-based treatment planning. Strahlenther Onkol 192(2):75–82. doi:10.1007/s00066-015-0900-9 CrossRefPubMed

26.

Fakhrian K, Oechsner M, Kampfer S, Schuster T, Molls M, Geinitz H (2013) Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : planning study in esophageal carcinoma. Strahlenther Onkol 189(4):293–300. doi:10.1007/s00066-012-0297-7 CrossRefPubMed

27.

Yu WW, Zhu ZF, Fu XL, Zhao KL, Mao JF, Wu KL, Yang HJ, Fan M, Zhao S, Welsh J (2014) Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol 190(11):979–986. doi:10.1007/s00066-014-0636-y CrossRefPubMed

Titel: Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer
verfasst von: Ichiro Ogino, M.D.
Shigenobu Watanabe
Kentaro Sakamaki
Yuka Ogino
Chikara Kunisaki
Kazuo Kimura
Publikationsdatum: 19.04.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2017
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1127-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2017

Wie lange sollte bis zur Beurteilung des Therapieansprechens nach Radiochemotherapie des Analkarzinoms gewartet werden?

Small bowel protection in IMRT for rectal cancer

Hypopharyngeal and upper esophageal ulceration after cervical spine radiotherapy concurrent with crizotinib

Spinal cord constraints in the era of high-precision radiotherapy

Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease

Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie